J&J to Buy Ollin Biosciences for $3.4B
Johnson & Johnson agrees to acquire biotech firm Ollin Biosciences, focused on eye disease therapies, in a deal worth up to $3.4 billion, including $2.2 billion upfront and potential milestone payments of $1.13 billion

Johnson & Johnson is set to acquire Ollin Biosciences, a biotech company specializing in eye disease therapies, in a deal valued at up to $3.4 billion. The acquisition includes an upfront payment of $2.2 billion, with potential regulatory and commercial milestone payments of up to $1.13 billion.
Ollin Biosciences, established in 2023, is focused on developing treatments for vision-threatening diseases. The company is backed by investment firms ARCH Venture Partners and Mubadala Capital.
The deal is expected to close before the end of 2026, expanding Johnson & Johnson's pipeline of eye disease therapies. This acquisition marks a significant investment by Johnson & Johnson in the biotech sector, particularly in the area of eye disease treatments.
## Why it matters The acquisition of Ollin Biosciences by Johnson & Johnson highlights the growing importance of biotech companies in the development of innovative treatments for various diseases. The deal also underscores the increasing focus on eye disease therapies, which affect millions of people worldwide. With this acquisition, Johnson & Johnson is poised to strengthen its position in the biotech industry and expand its portfolio of treatments for vision-threatening diseases.
The deal's value of up to $3.4 billion demonstrates the significant potential of Ollin Biosciences' pipeline and the importance of its research in the field of eye disease therapies. As the global biotech industry continues to evolve, acquisitions like this one are likely to play a crucial role in shaping the future of healthcare and the development of new treatments.




